These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 36313679)

  • 1. Targeting FGL2 in glioma immunosuppression and malignant progression.
    Ma X; Zhu H; Cheng L; Chen X; Shu K; Zhang S
    Front Oncol; 2022; 12():1004700. PubMed ID: 36313679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma.
    Latha K; Yan J; Yang Y; Gressot LV; Kong LY; Manyam G; Ezhilarasan R; Wang Q; Sulman EP; Eric Davis R; Huang S; Fuller GN; Rao A; Heimberger AB; Li S; Rao G
    J Natl Cancer Inst; 2019 Mar; 111(3):292-300. PubMed ID: 29947810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment.
    Miyazaki T; Ishikawa E; Sugii N; Matsuda M
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32707672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.
    Yan J; Kong LY; Hu J; Gabrusiewicz K; Dibra D; Xia X; Heimberger AB; Li S
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-10 in glioma.
    Widodo SS; Dinevska M; Furst LM; Stylli SS; Mantamadiotis T
    Br J Cancer; 2021 Nov; 125(11):1466-1476. PubMed ID: 34349251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogen-like protein 2: Its biological function across cell types and the potential to serve as an immunotherapy target for brain tumors.
    Zhang S; Rao G; Heimberger A; Li S
    Cytokine Growth Factor Rev; 2023 Feb; 69():73-79. PubMed ID: 36085259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
    Tang L; Zhang M; Liu C
    Front Immunol; 2022; 13():882257. PubMed ID: 35651605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Myeloid Cells in GBM Immunosuppression.
    Lin YJ; Wu CY; Wu JY; Lim M
    Front Immunol; 2022; 13():887781. PubMed ID: 35711434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of myeloid cells in the immunosuppressive microenvironment in gliomas.
    Locarno CV; Simonelli M; Carenza C; Capucetti A; Stanzani E; Lorenzi E; Persico P; Della Bella S; Passoni L; Mavilio D; Bonecchi R; Locati M; Savino B
    Immunobiology; 2020 Jan; 225(1):151853. PubMed ID: 31703822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T lymphocyte-targeted immune checkpoint modulation in glioma.
    Kelly WJ; Giles AJ; Gilbert M
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis of the Tumor Immune Microenvironment Landscape in Glioblastoma Reveals Tumor Heterogeneity and Implications for Prognosis and Immunotherapy.
    Zhao R; Pan Z; Li B; Zhao S; Zhang S; Qi Y; Qiu J; Gao Z; Fan Y; Guo Q; Qiu W; Wang S; Wang Q; Zhang P; Guo X; Deng L; Xue H; Li G
    Front Immunol; 2022; 13():820673. PubMed ID: 35309323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenomic analysis reveals LGALS1 contributes to the immune heterogeneity and immunosuppression in glioma.
    Chen Q; Han B; Meng X; Duan C; Yang C; Wu Z; Magafurov D; Zhao S; Safin S; Jiang C; Cai J
    Int J Cancer; 2019 Jul; 145(2):517-530. PubMed ID: 30613962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in clinical design of immunotherapy trials for malignant glioma.
    Rolle CE; Sengupta S; Lesniak MS
    Neurosurg Clin N Am; 2010 Jan; 21(1):201-14. PubMed ID: 19944979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions.
    Sattiraju A; Mintz A
    Adv Exp Med Biol; 2019; 1147():65-91. PubMed ID: 31147872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging patents in the therapeutic areas of glioma and glioblastoma.
    Harris M; Svensson F; Kopanitsa L; Ladds G; Bailey D
    Expert Opin Ther Pat; 2018 Jul; 28(7):573-590. PubMed ID: 29950117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGL1 and FGL2: emerging regulators of liver health and disease.
    Chen J; Wu L; Li Y
    Biomark Res; 2024 May; 12(1):53. PubMed ID: 38816776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications.
    Himes BT; Geiger PA; Ayasoufi K; Bhargav AG; Brown DA; Parney IF
    Front Oncol; 2021; 11():770561. PubMed ID: 34778089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of integrative molecular and clinical profiles of Fibrinogen-like protein 2 in gliomas using 1323 samples.
    Song Z; Wang Y; Du Y; Zhang Z; Yuan Y
    Int Immunopharmacol; 2020 Nov; 88():106894. PubMed ID: 32858440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small Molecule Immunomodulators as Next-Generation Therapeutics for Glioblastoma.
    Abdel-Rahman SA; Gabr M
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.